# Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure

> **NCT01060579** · PHASE2 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 217 (actual)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** AR-12286 0.5% ophthalmic solution
- **DRUG:** AR-12286 0.25% Ophthalmic solution
- **DRUG:** Latanoprost ophthalmic solution

## Key facts

- **NCT ID:** NCT01060579
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2014-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01060579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01060579, "Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01060579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*